阿戈美拉汀治疗首发抑郁症疗效及对肝功能的影响  

作　　者：邹展平 封敏 费玉娥[2] 郭子雷[2] 夏江明[2] 陶峰 林勇[2] 

机构地区：[1]浙江省海宁市第四人民医院,314400 [2]浙江省嘉兴市康慈医院,314500 [3]浙江省嘉善县第三人民医院,314100

出　　处：《浙江临床医学》2021年第1期88-89,92,共3页Zhejiang Clinical Medical Journal

基　　金：浙江省桐乡市重点科技计划项目(201801016)。

摘　　要：目的评估阿戈美拉汀治疗首发抑郁症的疗效,观察其对肝功能的影响。方法选取2018年1月至2019年6月首发抑郁症患者108例,随机分为观察组和对照组。观察组68例,给予阿戈美拉汀片治疗;对照组40例,给予艾司西酞普兰治疗。观察两组疗效及肝功能水平动态变化。结果治疗4周,HAMA总分、PSQI总分两组比较差异有统计学意义(P<0.05);治疗8周,HAMD低动力因子分、HAMA总分、SF-36总分两组比较差异有统计学意义(P<0.05)。治疗2周,两组ALT、ALP指标比较差异有统计学意义(P<0.05);治疗4周,两组ALT、AST指标比较差异有统计学意义(P<0.05);治疗8周,两组ALT、AST、ALP、TB指标比较差异有统计学意义(P<0.05)。结论阿戈美拉汀治疗首发抑郁症疗效优于艾司西酞普兰,对肝功能影响较小。Objective To evaluate the efficacy of Agomelatdne in the treatment of first episode depression and to observe its effect on liver function.Methods A total of 108 patients with first episode depression from January 2018 to June 2019 were randomly divided into observation group and control group.In the observation group,68 cases were treated with acomelatin tablets,while in the control group,40 cases were treated with escitalopram.The therapeutic effect and the dynamic changes of liver function were observed.Results After 4 weeks of treatment,Hama total score and PSQI total score had significant difference(P<0.05),and after 8 weeks of treatment,Hamd low motivation factor score,Hama total score and SF-36 total score had significant difference(P<0.05).After 2 weeks of treatment,ALT and ALP were significantly different between the two groups(P<0.05);after 4 weeks of treatment,ALT and AST were significantly different between the two groups(P<0.05);after 8 weeks of treatment,there was significant difference in ALT,AST,ALP and TB BETWEEN TWO GROUPS(P<0.05).Conclusion Agomelatine is more effective than Escitalopram in treating first episode depression and has less impact on liver function.

关 键 词：阿戈美拉汀 艾司西酞普兰 首发抑郁症 疗效 肝功能 

分 类 号：R74[医药卫生—神经病学与精神病学]